Age- and Sex-Specific Reference Intervals Across Life Span for Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 Ratio Measured by New Automated Chemiluminescence Assays
Open Access
- 1 May 2014
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (5), 1675-1686
- https://doi.org/10.1210/jc.2013-3060
Abstract
Context: Measurement of IGF-binding protein-3 (IGFBP-3) can aid the diagnosis of GH-related diseases. Furthermore, epidemiological studies suggest that IGFBP-3 and the molar IGF-I to IGFBP-3 ratio are associated with clinical end points like cancer or cardiovascular disease. However, their clinical use is limited by the lack of validated reference intervals. Objective: The objective of the study was the establishment of age- and sex-specific reference intervals for IGFBP-3 and the molar IGF-I to IGFBP-3 ratio by newly developed automated immunoassays. Setting: This was a multicenter study with samples from 11 cohorts from the United States, Canada, and Europe. Participants: A total of 14 970 healthy subjects covering all ages from birth to senescence participated in the study. Main Outcome Measures: Concentrations of IGFBP-3 and the IGF-I to IGFBP-3 ratio as determined by the IDS iSYS IGF-I and IGFBP-3 assays were measured. Results: Both the concentration of IGFBP-3 and the IGF-I to IGFBP-3 ratio are mainly determined by age. IGFBP-3 concentrations increase until the age of 22 years, with a plateau being visible between 15 and 25 years. Determined by the high peripubertal peak in IGF-I, the peak in the IGF-I to IGFBP-3 ratio occurs already around the age of 15 years, with a slightly earlier and higher peak in females. Beyond the age of 60 years, IGFBP-3 concentrations remain higher in females, whereas IGF-I as well as the IGF-I to IGFBP-3 ratio remains significantly higher in males. Conclusions: We present an extensive set of assay-specific age- and sex-adjusted normative data for concentrations of IGFBP-3 and the molar IGF-I to IGFBP-3 ratio and demonstrate distinct sex specific differences across the life span.Keywords
This publication has 49 references indexed in Scilit:
- Biochemical Characterization of Individual Human Glycosylated pro-Insulin-like Growth Factor (IGF)-II and big-IGF-II Isoforms Associated with CancerOnline Journal of Public Health Informatics, 2013
- Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infectionOncology Letters, 2011
- Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 Molar Ratio and Risk of Pancreatic Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialCancer Epidemiology, Biomarkers & Prevention, 2010
- Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human DiseaseEndocrine Reviews, 2009
- Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adultsGrowth Hormone & IGF Research, 2009
- IMMULITE® 2000 age and sex-specific reference intervals for alpha fetoprotein, homocysteine, insulin, insulin-like growth factor-1, insulin-like growth factor binding protein-3, C-peptide, immunoglobulin E and intact parathyroid hormoneClinical Biochemistry, 2008
- IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-AmericansCarcinogenesis: Integrative Cancer Research, 2007
- Central and Opposing Effects of IGF-I and IGF-Binding Protein-3 on Systemic Insulin ActionDiabetes, 2006
- Quantile regression via vector generalized additive modelsStatistics in Medicine, 2004
- Smoothing reference centile curves: The lms method and penalized likelihoodStatistics in Medicine, 1992